



COPY OF PAPERS
ORIGINALLY FILED

Dkt. 65019-DA-PCT-US/JPW/AJM

1644

\$

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Marc Feldmann and Ravinder N. Maini
Serial No. : 09/754,004 Examiner: P. Gambel
Filed : January 3, 2001 Group Art Unit: 1644
For : TNF α ANTAGONISTS AND METHOTREXATE IN THE
TREATMENT OF TNF-MEDIATED DISEASE

#8
JMS
6/6/02

1185 Avenue of the Americas
New York, New York 10036
May 10, 2002

RECEIVED

Assistant Commissioner for Patents
Washington, D.C. 20231

MAY 30 2002

TECH CENTER 1600/2900

Sir:

**COMMUNICATION IN RESPONSE TO
MARCH 12, 2002 RESTRICTION REQUIREMENT
AND PETITION FOR ONE-MONTH EXTENSION OF TIME**

This Communication is submitted in response to the March 12, 2002 Office Action issued by the United States Patent and Trademark Office in connection with the above-identified application. A response to the March 12, 2002 Office Action was due April 12, 2002. Applicants hereby petition for a one-month extension of time from April 12, 2002 to May 12, 2002. The required fee for a one-month extension of time is ONE HUNDRED AND TEN DOLLARS (\$110.00), and a check including this amount is enclosed. Accordingly, a response to the March 12, 2002 Office Action is now due May 12, 2002 and this response is being timely filed.

In the Office Action, the Examiner restricted pending claims 1-38, under 35 U.S.C. §121, to one of the following eight allegedly distinct inventions:

05/28/2002 ZJUHA1 00000044 09754004

01 FC:115

110.00 OP

Applicants: Marc Feldmann, et al.
Serial No.: 09/754,004
Filed: January 3, 2001
Page 2

- I. Claims 1-6, 11-19 and 24-38, drawn to methods of treating TNF-mediated diseases with methotrexate and TNF-specific antibodies;
- II. Claims 1-6, 20-23 and 24-38, drawn to methods of treating TNF-mediated diseases with methotrexate and p55TNF α receptors;
- III. Claims 1-6, 20-23 and 24-38, drawn to methods of treating TNF-mediated diseases with methotrexate and p75TNF α receptors;
- IV. Claims 1-8 and 24-38, drawn to methods of treating TNF-mediated diseases with methotrexate and pentoxifylline;
- V. Claims 1-8 and 24-38, drawn to methods of treating TNF-mediated diseases with methotrexate and rolipram;
- VI. Claims 1-6, 9 and 24-38, drawn to methods of treating TNF-mediated diseases with methotrexate and thalidomide;
- VII. Claims 1-6, 9 and 24-38, drawn to methods of treating TNF-mediated diseases with methotrexate and tenidap; and
- VIII. Claims 1-6, 10 and 24-38, drawn to methods of treating TNF-mediated diseases with methotrexate and A2b adenosine receptor agonists and enhancers.

The Examiner also required, under 35 U.S.C. §121, election of a single disclosed species from the following: